Defective interferon-gamma production in ataxia-telangiectasia. 1984

R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti

The in vitro production of interferon-alpha and -gamma (IFN) by peripheral blood mononuclear cells from four patients with ataxia-telangiectasia was compared to that of healthy controls. Normal values of IFN-alpha were obtained in all cases. However, patients with ataxia-telangiectasia showed a great reduction or absence of IFN-gamma production after induction with either staphylococcal enterotoxin B or galactose oxidase. This defect was accompanied by the absence of secretion of another lymphokine, namely, interleukin 2 (IL-2), in one case. Lymphoproliferative response to phytohemagglutinin (PHA) was severely depressed in all patients. Near normal values of T lymphocytes were found, but the ratio of OKT4+/OKT8+ subsets was reduced in most patients, due to a decrease of OKT4+ lymphocytes. Deficiency of IFN-gamma may contribute to the abnormalities of immune functions and immunoregulation observed in ataxia-telangiectasia, and it may represent an additional cause of the high incidence of viral infections and neoplasia in this disease.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
April 1976, Nature,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
December 1998, Genes & development,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
January 1985, Kroc Foundation series,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
December 1998, Radiation research,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
February 1987, Arthritis and rheumatism,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
January 1990, Acta biologica Hungarica,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
August 2000, International journal of radiation biology,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
December 2006, Clinical and experimental immunology,
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
June 1983, Journal of immunology (Baltimore, Md. : 1950),
R Paganelli, and M R Capobianchi, and P M Matricardi, and L Cioè, and R Seminara, and F Dianzani, and F Aiuti
June 1999, FEBS letters,
Copied contents to your clipboard!